Cell and Gene Therapy CDMO market Archives

Driven by the rising incidence of cancer and other targeted illnesses, the robust CGT pipeline, the fast-growing field of cell and gene therapy research, significant venture capital financing, and technical advancements. The development and approval of CAR-T cell therapies such as Kymriah and Yescarta and their success in combating hematological malignancies, has further boosted investment in CGT. Robust CGT pipeline with growing number of product approvals, strong support from large pharma and biotech, and consistent investor enthusiasm (~$20 bn raised in 2020) is set to boost the demand for CGT services. A growing pipeline of therapies are nearing regulatory decisions. Out of 1,220 ongoing clinical trials in 2020, 152 were in Phase 3 — FDA and EMA predict approval of 10-20 cell and gene therapies each year by 2025. Find A Free Sample of Our Research Report @ https://meditechinsights.com/cell-and-gene-therapy-cdmo-market/request-sample/ Growing Demand for Full-service/One-stop-shop CDMOs Full-service CDMOs that can assist with both development and manufacturing are in utmost demand. Much of the gene therapy development as of late has been from smaller biotech companies or research universities who rely on CDMOs from preclinical development through packaging. Big pharma and biopharma companies also prefer a full-service CDMO to speed up the timeline and free up resources to focus on innovation and marketing. “There is growing demand for Cell and Gene Therapy CTDMOs who can offer integrated development, manufacturing, and testing services. For cell and gene therapy companies, outsourcing manufacturing and testing operations to a capable CTDMO can reduce development timelines, provide supplementary capacity, and ultimately control costs.”- Senior Director, Tier 1 CGT CDMO, US Greater Focus on Long-term Strategic Collaborations Cell and gene therapy industry has witnessed multi-fold rise in the number of collaborations between manufacturers/innovators and CDMOs in the form of joint ventures, manufacturing agreements, licensing agreements, service alliances etc. For instance, in April 2021, AavantiBio partnered with Catalent to support the development and manufacturing of AavantiBio’s gene therapies. Also, recent M&A activity reflects growing interest in cell & gene therapy market. Ex. Astellas acquired Audentes Therapeutics for $3 bn (Jan 2020), Roche acquired Spark Therapeutics for $4.8 bn (Dec 2019) to expand into CGT. Substantial Outsourcing in CGT Industry due to Lack of Internal Capabilities The current level of outsourcing in CGT exceeds 60% which is far above the level of outsourcing seen in overall pharma/biologics field. Cell & Gene therapy is a complex field requiring high level of expertise. Also, it has costly production and different manufacturing process/infrastructure requirements as compared to traditional small molecules. Big pharma currently lacks production-ready infrastructure and are increasingly looking for CGT CDMOs to enter/expand their presence in fast-growing CGT market. Moreover, rising influx of small biotechs in the market with limited/no manufacturing capabilities and/or development expertise further provides growth opportunities for CGT CDMOs. With only ~150 CMOs having CGT capabilities, such demand supply gap offers ample growth potential for CDMOs with CGT capabilities. North America is the Largest and Fastest Growing Region North America is the largest and fastest growing cell & gene therapy (CGT) CDMO market. It is expected to continue its dominance in the coming 5 years owing to growing manufacturing capacity for CGTs, favorable regulatory approval process, growing cell and gene therapy approvals per year, and strong product pipeline of CGTs in the U.S. The regulatory approval process in the US is evolving and becoming favorable for innovators for developing cell and gene therapy products. The U.S. FDA is designating orphan drug status, breakthrough designation, accelerated approvals, and regenerative medicine advanced therapy (RMAT) designations for cell and gene therapies to expedite the approval process. Competitive Landscape Analysis: Cell and Gene Therapy CDMO Market The cell & gene therapy (CGT) CDMO market is marked by presence of both established players and several small and mid-sized players. Some of the leading players include Lonza, Catalent, Patheon, Wuxi Advanced Therapies and Charles River Laboratories. Other promising players include Vive Biotech, SK Bioscience, Fujifilm, Vibalogics, Exothera, Takara, Oxford Biomedica, Viralgen, AGC Biologics, among several others.

Tag: Cell and Gene Therapy CDMO market

Global Cell and Gene Therapy CDMO market is expected to grow at a CAGR of over 25%, reaching $5 billion by 2025.

Global Biologics CDMO Market is set to soar at substantial CAGR of 14–16% in the next five years.

Oncology Information System Market Projected to Witness High Growth of 8% from 2024 to 2029

The Transplantation Market Expected to Grow at a 9-10% CAGR by 2029, Fueled by Advancements in Transplant Technologies

The Bioburden Testing Market Maintains Strong CAGR with Growing Demand for Sterilization Assurance

The Fluoroscopy Equipment Market is Poised to grow at a CAGR of 5–7%.

The Bionic Contact Lenses Market is poised to grow at a high CAGR of 11-13%

Global Biosimulation Market Envisions a Promising Future to Have a High 15-20% Growth by 2028

Global Intraocular Lens (IOLs) Market Expecting a Decent 5-6% CAGR in the Next 5 Years

The Cardiology Information System (CIS) Market is projected to grow at a healthy CAGR of 8-10% over the next few years.

Global FemTech Market valued at ~$22 billion (2020) is projected to rise at a healthy growth rate of 15% by 2025.